| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | AI1H |
| WB Predicted band size | 86 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human ITGB6 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于ITGB6抗体的3篇文献摘要信息，供参考：
---
1. **文献名称**: *Targeting of αvβ6 integrin by antibody inhibits TGF-β activation in human lung fibrosis*
**作者**: Horan GS et al.
**摘要**: 该研究开发了针对αvβ6整合素(含ITGB6亚基)的单克隆抗体，发现其可通过阻断TGF-β信号通路抑制肺纤维化小鼠模型的疾病进展，为抗纤维化治疗提供潜在策略。
---
2. **文献名称**: *Integrin αvβ6 promotes tumor progression in colorectal cancer by regulating EMT and immune microenvironment*
**作者**: Zhao J et al.
**摘要**: 研究利用ITGB6特异性抗体抑制αvβ6整合素活性，发现其能降低结直肠癌细胞上皮-间质转化(EMT)能力，并增强肿瘤微环境中T细胞浸润，提示抗体在癌症免疫治疗中的应用潜力。
---
3. **文献名称**: *Anti-αvβ6 antibodies as diagnostic markers in oral squamous cell carcinoma*
**作者**: Ahmed Z et al.
**摘要**: 研究验证了一种高亲和力ITGB6抗体在口腔鳞癌组织中的特异性结合能力，证明其可作为早期诊断标志物，并揭示αvβ6表达水平与患者预后呈负相关。
---
如需具体文献全文，建议通过PubMed或Sci-Hub输入标题检索。
**Background of ITGB6 Antibody**
The ITGB6 antibody targets integrin beta-6 (ITGB6), a subunit of the αvβ6 heterodimer, a cell surface receptor involved in cell-matrix interactions. Integrin αvβ6 binds to extracellular matrix (ECM) proteins containing an RGD motif, such as fibronectin and tenascin, and plays critical roles in epithelial cell adhesion, migration, and signaling. Notably, αvβ6 is highly expressed in epithelial tissues during wound healing, fibrosis, and cancer, but exhibits limited expression in healthy adult tissues.
ITGB6 antibodies are valuable research tools for studying αvβ6's functional roles, particularly its activation of transforming growth factor-beta (TGF-β), a key regulator of tissue remodeling and immune responses. Dysregulated αvβ6 expression is linked to pathological conditions, including idiopathic pulmonary fibrosis, cancer progression, and chronic inflammation. In cancer, elevated ITGB6 levels correlate with tumor invasion, metastasis, and poor prognosis.
Therapeutic ITGB6 antibodies are under exploration for blocking αvβ6-mediated TGF-β activation or ECM interactions to inhibit fibrosis or tumor growth. Diagnostic applications focus on detecting ITGB6 overexpression in diseased tissues as a biomarker. Challenges include optimizing specificity and minimizing off-target effects. Overall, ITGB6 antibodies hold promise for both understanding αvβ6 biology and developing targeted therapies for fibrosis and cancer.
×
